Most research to date has concentrated on CD4+ T lymphocytes' role as both facilitators and moderators in MS pathogenesis and as a result, inflammatory CD4+ T cell responses are frequently targeted in MS therapy. The gene discussed is CD4; the disease is myeloid sarcoma.